The final days of 2023 delivered a one-two punch to the healthcare giant UnitedHealth Group. Within a 48-hour span, two significant regulatory and legal developments emerged, creating a complex pressure scenario for the company’s core business segments.
Legal Action Targets Federal Treatment Guidelines
On December 24, a coalition of 19 U.S. states filed a lawsuit against the Department of Health and Human Services, specifically targeting Health Secretary Robert F. Kennedy Jr. The legal challenge focuses on newly established federal guidelines concerning treatments for gender dysphoria. The department has classified certain therapies for adolescents as unsafe and has threatened to exclude providers from Medicare and Medicaid programs if they continue to offer them.
This litigation presents a direct risk to UnitedHealth’s Optum division, which operates one of the nation’s largest networks of physicians and clinics. Should federal funding be withdrawn from non-compliant providers, Optum could face substantial revenue losses. The ensuing legal battle is expected to last for months, undermining near-term operational certainty.
New Drug Pricing Model Squeezes Pharmacy Margins
Preceding the lawsuit, on December 23, the Centers for Medicare & Medicaid Services (CMS) unveiled a new pricing framework for weight-loss medications, named the “BALANCE” model. This initiative takes direct aim at the costs of GLP-1 agonist drugs. Its central feature involves CMS negotiating prices directly with pharmaceutical manufacturers for Medicaid and Medicare Part D plans.
A transitional program capping monthly out-of-pocket costs for Medicare beneficiaries at $50 is set to begin in July 2026, with full implementation scheduled for 2026 and 2027.
For UnitedHealth, this policy translates into mounting margin pressure within its Pharmacy Benefit Management (PBM) operations. The government is imposing strict price ceilings on the lucrative GLP-1 drug market at a time when the company is already contending with significant profitability issues.
Should investors sell immediately? Or is it worth buying Unitedhealth?
Earnings Picture Darkens Ahead of Q4 Report
The company’s upcoming fourth-quarter earnings report, due in late January, is anticipated to reflect these struggles. Analyst forecasts paint a bleak picture, with adjusted earnings per share expected to land between $2.09 and $2.12. This would represent a sharp decline of nearly 69% compared to the same quarter last year.
A key driver of this downturn is the Medical Care Ratio, which spiked to 89% at times, driven by unexpectedly high utilization of outpatient and physician services. While revenues continue to grow—rising over 12% year-over-year in Q3—the conversion of that top-line growth into bottom-line profit has faltered. For the full 2025 fiscal year, market experts project adjusted EPS of approximately $16.30, a historically severe contraction.
Institutional Investors Show Diverging Strategies
This climate of uncertainty is visible in the activity of major shareholders. During the third quarter, Chatham Capital Group reduced its stake in UnitedHealth by 75.7%, a move mirrored by other large institutional investors who also trimmed their positions.
However, the steep decline in the share price—now trading around $326 after reaching a 52-week high above $600—has attracted value-oriented buyers. Strong Tower Advisory Services, for instance, increased its holding by 36%.
With the equity valued at roughly 17 times forward earnings and offering a dividend yield of 2.7%, the stock may hold appeal for long-term investors. In the short term, however, regulatory headwinds and weak earnings momentum dominate the narrative. The combined effect of drug pricing pressure and legal risks in care delivery continues to weigh heavily on the investment case.
Ad
Unitedhealth Stock: Buy or Sell?! New Unitedhealth Analysis from December 24 delivers the answer:
The latest Unitedhealth figures speak for themselves: Urgent action needed for Unitedhealth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 24.
Unitedhealth: Buy or sell? Read more here...
